Gapping up
In reaction to strong earnings/guidance: CHKE +13.2%, CE +13.2%, MAT +7.4%, SM +3.7%, FHN +3.1%, CYT +2.8%, SLB +2.6%, ANCX +2.3%, RAI +1.4%, MUX +1%, MFLX +0.7%, CMA +0.5%
M&A news: UNXL +17.8% (acquires Atmel's (ATML) XSense assets and operations), IGTE +7.5% (Capgemini (CGEMY) and Atos M&A speculation), HCBK +5.9% (Hudson City Banc and M&T Bank (MTB) have agreed to extend the date after which either party may elect to terminate their Agreement and Plan of Merger)
Other news: RXII +24.3% (confirms its receives Orphan Drug Designation for Samcyprone from the FDA to treat malignant melanoma ), TRXC +21% (Announces Completion of GLP Studies; SurgiBotTM system FDA 510(k) filing on track for mid-2015 submission), ONCY +15.9% (confirms its receipt of Orphan Drug Designation from the FDA for REOLYSIN), NVGN +14.4% (signs an MOU with the Feinstein Institute for Medical Research to collaborate on developing treatments for brain cancers), GMO +14% (announces strategic partnership with AMER International Group to become a major shareholder), SSH +5.8% (announces that the FDA has reviewed co's submission regarding the COUNTER HF's U.S. pivotal study pause and requested minor protocol changes be submitted in order to receive approval to resume patient enrollment ), HOT +4% (may be a possible activist target, according to Bloomberg), GIG +3.7% (Fred H. Brenner disclosed 7.05% passive stake in 13G filing), SM +3.7% (announced that Q1 production is expected to be 16.8 MMBOE, or 186.4 MBOE/d; borrowing base maintained at $2.4 bln), BSX +1.8% (enrolls first patient in new study designed to demonstrate the effect of the Vessix Renal Denervation System), ARIA +1.6% (announces updated clinical data on Brigatinib to treate ALK+ non-small cell lung cancer), ARCO +1.5% ( announces that coffee sales at McDonald's (MCD) Brazil set a new 7-day record in early April, serving 66 mln liters between April 1 and April 7, up 34% from the same period a year ago)
Analyst comments: ROSG +6.1% (upgraded to Buy from Hold at Cantor Fitzgerald), CYTR +4% (initiated with an Outperform at Oppenheimer), MNTA +2.9% (target raised to $24 from $16 at Leerink Partners; Outperform; also announced the upcoming presentation of two posters), ICPT +2.6% (initiated with a Buy at UBS), OPWR +1.4% (initiated with an Outperform at William Blair),RCPT +0.8% (initiated with a Buy at UBS), CYBR +0.8% (initiated with a Mkt Outperform at JMP Securities), RGC +0.6% (initiated with a Outperform at RBC Capital Mkts)
In reaction to strong earnings/guidance: CHKE +13.2%, CE +13.2%, MAT +7.4%, SM +3.7%, FHN +3.1%, CYT +2.8%, SLB +2.6%, ANCX +2.3%, RAI +1.4%, MUX +1%, MFLX +0.7%, CMA +0.5%
M&A news: UNXL +17.8% (acquires Atmel's (ATML) XSense assets and operations), IGTE +7.5% (Capgemini (CGEMY) and Atos M&A speculation), HCBK +5.9% (Hudson City Banc and M&T Bank (MTB) have agreed to extend the date after which either party may elect to terminate their Agreement and Plan of Merger)
Other news: RXII +24.3% (confirms its receives Orphan Drug Designation for Samcyprone from the FDA to treat malignant melanoma ), TRXC +21% (Announces Completion of GLP Studies; SurgiBotTM system FDA 510(k) filing on track for mid-2015 submission), ONCY +15.9% (confirms its receipt of Orphan Drug Designation from the FDA for REOLYSIN), NVGN +14.4% (signs an MOU with the Feinstein Institute for Medical Research to collaborate on developing treatments for brain cancers), GMO +14% (announces strategic partnership with AMER International Group to become a major shareholder), SSH +5.8% (announces that the FDA has reviewed co's submission regarding the COUNTER HF's U.S. pivotal study pause and requested minor protocol changes be submitted in order to receive approval to resume patient enrollment ), HOT +4% (may be a possible activist target, according to Bloomberg), GIG +3.7% (Fred H. Brenner disclosed 7.05% passive stake in 13G filing), SM +3.7% (announced that Q1 production is expected to be 16.8 MMBOE, or 186.4 MBOE/d; borrowing base maintained at $2.4 bln), BSX +1.8% (enrolls first patient in new study designed to demonstrate the effect of the Vessix Renal Denervation System), ARIA +1.6% (announces updated clinical data on Brigatinib to treate ALK+ non-small cell lung cancer), ARCO +1.5% ( announces that coffee sales at McDonald's (MCD) Brazil set a new 7-day record in early April, serving 66 mln liters between April 1 and April 7, up 34% from the same period a year ago)
Analyst comments: ROSG +6.1% (upgraded to Buy from Hold at Cantor Fitzgerald), CYTR +4% (initiated with an Outperform at Oppenheimer), MNTA +2.9% (target raised to $24 from $16 at Leerink Partners; Outperform; also announced the upcoming presentation of two posters), ICPT +2.6% (initiated with a Buy at UBS), OPWR +1.4% (initiated with an Outperform at William Blair),RCPT +0.8% (initiated with a Buy at UBS), CYBR +0.8% (initiated with a Mkt Outperform at JMP Securities), RGC +0.6% (initiated with a Outperform at RBC Capital Mkts)